CLN6 (Ceroid Lipofuscinosis, Neuronal 6) is an endoplasmic reticulum membrane protein belonging to the ceroid lipofuscinosis family. Mutations in CLN6 cause variant late infantile neuronal ceroid lipofuscinosis (vLINCL), a fatal neurodegenerative lysosomal storage disorder characterized by progressive loss of neuronal function, visual impairment, and premature death.
| CLN6 - Ceroid Lipofuscinosis, Neuronal 6 | |
|---|---|
| Protein Name | Ceroid lipofuscinosis neuronal 6 protein |
| Gene Symbol | CLN6 |
| UniProt ID | Q9NRA8 |
| Molecular Weight | 33 kDa |
| Subcellular Localization | Endoplasmic Reticulum |
| Protein Family | Ceroid lipofuscinosis (CLN) family |
CLN6 encodes an ER membrane protein mutated in variant late infantile neuronal ceroid lipofuscinosis (vLINCL). CLN6 functions as a transmembrane protein that facilitates lysosomal enzyme trafficking and participates in autophagy-lysosomal pathway regulation. The protein is highly expressed in neurons and plays a critical role in maintaining cellular homeostasis.
CLN6 functions as a "molecular chaperone" or "facilitator" for lysosomal enzyme trafficking from the endoplasmic reticulum to the lysosome. The protein interacts with lysosomal enzymes and assists in their proper folding and transport through the secretory pathway [1].
CLN6 plays a role in regulating autophagy, the cellular degradation process essential for neuronal survival. Loss of CLN6 function leads to impaired autophagic flux and accumulation of autophagic vacuoles in neurons [2].
The protein participates in the unfolded protein response (UPR) and ER-associated degradation (ERAD) pathways. Dysfunction leads to chronic ER stress, activation of apoptotic pathways, and eventual neuronal death [3].
Clinical Features:
Over 40 pathogenic mutations identified in CLN6, including:
While direct enzyme replacement is challenging due to the ER localization of CLN6, gene therapy approaches aim to deliver functional CLN6 to neurons [4].
AAV-vector mediated gene delivery of CLN6 has shown promise in preclinical models, with clinical trials underway for related forms of Batten disease.
Human stem cell-derived neural progenitor cells are being investigated for cell replacement therapy.
Mouse models (Cln6^nclf and Cln6^nd) recapitulate key features of human disease and are used for therapeutic testing.
The study of Cln6 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Mole SE, et al. CLN6 disease: genetics and biology. Biochim Biophys Acta. 2020
[2] Wheeler RB, et al. CLN6 mutations cause vLINCL. Am J Hum Genet. 2002
[3] Collins F, et al. CLN6 and ER stress. Autophagy. 2023
[4] Bond M, et al. Gene therapy for CLN6 disease. Mol Ther. 2024